Previous Article | Next Article 
Infection and Immunity, November 1998, p. 5433-5442, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Antibody Response to Fibronectin-Binding Adhesin
FnbpA in Patients with Staphylococcus aureus
Infections
Fabrizia
Casolini,1
Livia
Visai,1
Danny
Joh,2
Pier Giulio
Conaldi,3
Antonio
Toniolo,3
Magnus
Höök,2 and
Pietro
Speziale1,*
Department of Biochemistry, University of
Pavia, 27100 Pavia,1 and
Department of
Clinical and Biological Sciences, University of Pavia, 21100 Varese,3 Italy, and
Center for
Extracellular Matrix Biology, Institute of Biosciences and
Technology, Texas A&M University, Houston, Texas
770302
Received 24 August 1998/Accepted 3 September 1998
 |
ABSTRACT |
We have analyzed antibody reactivity to a fibronectin-binding
microbial surface component that recognizes adhesive matrix molecules
(MSCRAMM) in blood plasma collected from patients with staphylococcal
infections. All patients had elevated levels of anti-MSCRAMM antibodies
compared to those of young children who, presumably, had not been
exposed to staphylococcal infections. The anti-MSCRAMM antibodies
preferentially reacted with the ligand-binding repeat domain of the
adhesin. However, these antibodies did not inhibit
fibronectin binding. Essentially, all patients had
antibodies which specifically recognized the fibronectin-MSCRAMM
complex but not the isolated components. Epitopes recognized by
these anti-ligand-induced binding sites antibodies were found
in each repeat unit of the MSCRAMM. These results demonstrate that
staphylococci have bound fibronectin some time during infection and
that each repeat unit in the MSCRAMM can engage in ligand
binding. Furthermore, our previously proposed model, suggesting that an
unordered structure in the MSCRAMM undergoes a conformational
change upon ligand binding (K. House-Pompeo, Y. Xu, D. Joh, P. Speziale, and M. Höök, J. Biol. Chem.
271:1379-1384, 1996), is presumably operational in patients during
infections.
 |
INTRODUCTION |
Adherence to host tissues is the
initial critical step in the pathogenic process of most bacterial
infections. Tissue adherence is mediated by bacterial surface
components called adhesins, which recognize target ligands on host
cells or in the extracellular matrix. Because of the importance of host
tissue adherence in the pathogenic process, bacteria have adopted
strategies to secure adhesion steps and to protect adhesins
against attacks by the host defense system. Adhesins on bacteria which
are extracellular pathogens are particularly vulnerable, since
throughout their lives in an animal these organisms are exposed to the
host's defense systems. We have used the abbreviation MSCRAMM
(microbial surface component recognizing adhesive matrix molecules) for
the family of surface proteins binding to extracellular matrix
molecules (11, 12). Molecular studies of MSCRAMM have
revealed unexpectedly sophisticated mechanisms of ligand interactions
in which host systems are often mimicked and great efforts are made to
avoid detection by the host's immune system.
Fibronectin (Fn)-binding MSCRAMM are present on many pathogenic
gram-positive bacteria. To date, the sequences of almost a dozen of
these MSCRAMM have been determined (1, 4-5, 8-10, 13-17).
Most have very similar structural organizations and molecular sizes of
around 100 kDa. The N terminus contains a long signal sequence
characteristic of many exported proteins in gram-positive bacteria.
Following is a long stretch of unique sequence, which may be
interrupted by a 30- to 35-amino-acid-(aa) repeated motif of unknown
function. The primary ligand-binding domain consists of three to
six repeats of a 40- to 50-aa motif. Synthetic peptides mimicking
individual repeat units often bind Fn and effectively inhibit the
binding of Fn to bacteria. The ligand-binding domain is found
just outside a cell wall attachment region present in many
surface proteins on gram-positive bacteria. At the C terminus is a
putative transmembrane segment rich in hydrophobic residues, followed
by a short cytoplasmic domain dominated by positively charged
residues. A model of an Fn-binding MSCRAMM is presented in Fig.
1.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of recombinant proteins
containing fragments of MSCRAMM FnbpA. All the segments were expressed
in fusion with GST carrier. Fn-binding repeat units are indicated by
Du, D1, D2, D3, and D4; S, signal sequence; W, cell wall spanning
region; M, membrane-spanning region.
|
|
We recently demonstrated that the ligand-binding domains of the
Fn-binding MSCRAMM do not have an organized structure but that
a conformation is induced in the repeat units on ligand binding (6). This induced fit conformation could be detected by
a specific monoclonal antibody which does not react with unoccupied
MSCRAMM (16). We speculated that this induced-fit
mechanism of ligand binding might affect the production of
inhibiting antibodies, interfering with the Fn-MSCRAMM
interaction.
In the present study, we have examined the antibody response
and specificity to the staphylococcal Fn-binding MSCRAMM FnbpA in
patients with staphylococcal infections.
 |
MATERIALS AND METHODS |
Sera.
Serum specimens from 33 individuals with
staphylococcal infections (Staphylococcus aureus) were
obtained from the Ospedale di Circolo, Varese, Italy. All sera were
from patients ranging from 21 to 86 years of age, with the majority of
patients over 65 years old. Antibodies from the sera were purified by
chromatography on protein A-Sepharose (Pharmacia), and the
concentration of the purified immunoglobulin G (IgG) was quantitated by
absorbance at 280 nm, with human IgG as the standard. Control IgG was
obtained from pooled sera of healthy 2-year-old children. Analysis of
IgG from individual children suggests that children have a uniformly low reactivity to the Fn-binding protein FnbpA from S. aureus. The patients were diagnosed with a variety of
staphylococcal infections, including sepsis, pneumonia, and
peritonitis. S. aureus was the only pathogen isolated in
most cases, although some multimicrobial infections were recorded. In
general, blood samples were obtained 2 days to 3 weeks after the
original diagnoses. The histories of the patients were not available.
Isolation and labeling of ligands.
Human Fn was
prepared as previously reported (18). The N-terminal Fn
fragment (N29) was isolated as described previously (6). The N29 fragment was 125I labeled with
IODO-BEADS iodination reagent as recommended by the manufacturer
(Pierce, Rockford, Ill.).
Recombinant proteins.
Recombinant proteins were expressed
from plasmids derived from pGEX-2T (Pharmacia) or pGEX-2H (see
below). The pGEX vectors drive the production of fusion proteins
in which gluthatione S-transferase (GST) precedes the unique
polypeptide segment encoded by the inserted DNA. The N-terminal GST
carrier allows the fusion proteins to be purified by affinity
chromatography with gluthatione-coupled matrix.
DNA fragments encoding the polypeptide segments indicated in Fig. 1
were produced by PCR and cloned into the vector as previously reported
(7). Table 1 describes the
oligonucleotide primers used in PCR and the vector used for
cloning each PCR fragment. To construct the plasmid expressing
GST-UA, GST-UB, and GST-UC, DNA amplified with the indicated primers
was cloned into the BamHI/HindIII site of the
vector pGEX-2H. This vector is a modified version of pGEX-2T in which
the SmaI restriction sequence was replaced by a
HindIII restriction sequence as follows. A
double-stranded oligonucleotide fragment, 5'GGAAGCTTCC3',
was blunt-end ligated to pGEX-2T digested with SmaI.
The resulting vector, named pGEX-2H, lacks the SmaI
restriction sequence but possesses a HindIII restriction sequence. Table 1 describes the oligonucleotide primers used in PCR and
the vector used for the amplified fragment.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Oligonucleotide primers and vectors used in the
construction of plasmids expressing recombinant Fn-binding
protein fragments
|
|
ELISA.
Igs isolated from human sera were tested for
antibodies against FnbpA recombinant proteins by enzyme-linked
immunosorbent assay (ELISA). Microtiter wells (Costar, Cambridge,
Mass.) were incubated overnight at 4°C with 100 µl of 50 mM sodium
carbonate, pH 9.5, containing 10 µg of protein per ml. Additional
protein binding sites in the wells were blocked by incubation for
1 h with 200 µl of 2% (wt/vol) bovine serum albumin (BSA) in 10 mM sodium phosphate, pH 7.4, containing 0.13 M NaCl
(phosphate-buffered saline; PBS). The wells were then washed five times
with PBST (0.1% Tween 20 in PBS-NaCl) and incubated with 2 µg of
antibody dissolved in 100 µl of 2% BSA in PBS at 22°C. Unbound
antibody was removed by washing the wells five times with PBST. Bound
antibody was detected by incubation (1 h at 37°C) with
peroxidase-conjugated rabbit anti-human IgG (Dako, Gostrup, Denmark)
diluted 1:2,000. After being washed the conjugated enzyme was reacted
with o-phenylenediamine dihydrochloride (Sigma), and the
absorbance at 492 nm was monitored with a microplate reader (Bio-Rad).
Fn-binding assay.
Binding of 125I-labeled
N29 to surface-immobilized MSCRAMM was performed on microtiter
plates. Wells were coated with 100 µl of GST-Du1234 (10 µg/ml) in
50 mM sodium carbonate, incubated overnight at 4°C, and then
subjected to blocking with 200 µl of 2% (wt/vol) BSA in PBS. The
wells were subsequently incubated for 2 h at 37°C with
125I-labeled N29 (8 × 104 cpm), and after
extensive washing (five times) with PBST, radioactivity associated with
the wells was quantitated with a gamma counter. The binding of
125I-labeled N29 to staphylococci was quantitated as
described previously (16).
Isolation of anti-ligand-induced binding site (LIBS) antibodies
by affinity chromatography on GST-Du1234-Sepharose.
Eight
milligrams of IgG isolated from patient 5 was passed through a
gelatin-Sepharose column to remove possible contaminating Fn. This
material was subsequently passed through a column (1 by 4 cm) of
Sepharose 4B coupled with GST-Du1234 recombinant protein and
equilibrated with PBS-azide. The column was washed with
equilibration buffer (PBS) until a stable baseline level of
absorbance at 280 nm of the column effluent was observed (flowthrough)
and then with 0.4 M NaCl in 10 mM phosphate buffer, pH 7.4. The
material which specifically bound to the column was eluted with
0.1 M glycine, pH 2.8, and the fractions were neutralized with 1 M
Tris. The unadsorbed material and the material bound and eluted
from the column were analyzed by ELISA and by Western blot analysis and dot blot analysis.
Western blotting.
FnbpA recombinant GST-Du1234 protein was
run in sodium dodecyl sulfate (SDS)-10% polyacrylamide gel under
reducing conditions and then electroblotted onto nitrocellulose
membranes (Sartorius, Gottingen, Germany) for 2 h at 200 mA in
transfer buffer (20 mM Tris-HCl, 150 mM glycine, 20% [vol/vol]
methanol, pH 8.3). The membranes were then treated for 1 h with a
solution containing 5% (wt/vol) dried skim milk in TBS (20 mM Tris-HCl
containing 0.5 M NaCl, pH 7.5), washed three times for 10 min each time
with TBS, and followed by 1 h of incubation with 0.7 µg of N29
per ml in 1% milk in TTBS (TBS containing 0.05% Tween 20). Membranes were washed and incubated for 2 h with IgG (0.7 µg/ml), washed three times for 10 min each time in TTBS, and subsequently incubated for 1 h in TTBS containing 1% milk and 5,000-fold-diluted
horseradish peroxidase-conjugated rabbit anti-human IgG (Dako). After
being washed, the membrane was treated with enhanced chemiluminescence detection reagents (NEN, Boston, Mass.) according to the procedure recommended by the manufacturer and exposed to X-ray film for 30 to
60 s.
Dot blot analysis.
Affinity membranes of Immobilon AV
(Millipore) were activated in PBS for 1 min and then dried with filter
paper. Recombinant GST-Du1234 protein (100 ng) dissolved in
the coupling buffer (0.5 M KH2PO4, pH 7.4) was
spotted and covalently bound to the membrane. To detect the
immunoreactive spots, the membrane was probed with antibodies in the presence and absence of N29 and treated following the
procedure described for the Western blot assay.
 |
RESULTS |
IgG reacts with the repeat domain of the
Fn-binding MSCRAMM.
Different segments of the S. aureus Fn-binding MSCRAMM were expressed as recombinant proteins
and purified. The reactivity of IgG to these segments coated onto
microtiter plates was subsequently examined (Fig.
2). In general, more antibodies bound to
wells coated with the ligand-binding repeat domain GST-Du1234 than to wells coated with any other recombinant MSCRAMM domain.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Mapping of epitopes in GST-FnbpA fusion protein
derivatives. GST-FnbpA polypeptides GST-UA, GST-UB, GST-UC and
GST-Du1234 (1 µg in 100 µl) were immobilized in microtiter wells
and probed with IgG preparations (2 µg in 100 µl). Bound antibody
was detected as described in Materials and Methods. Pooled sera from
2-year-old children were used as the control (*). Results are
expressed as means ± standard deviations (error bars). Each
sample point was done in duplicate.
|
|
Patients varied substantially in terms of IgG reactivity to the
GST-Du1234 protein. IgG from patients 20, 22, and 28 seemed
to
bind to the MSCRAMM at levels that were the same or lower than
those of
the control IgG isolated from young children with no
history of
staphylococcal infection. On the other hand, most of
the IgG from the
adults bound to the MSCRAMM at levels significantly
higher than those
of the control IgG, and patients 18 and 23 gave
a 10-fold-higher
response signal. Taken together, these results
suggest that patients
exposed to staphylococcal infections respond
by producing antibodies to
the Fn-binding MSCRAMM that preferentially
target the ligand-binding
domain of the MSCRAMM. A sample of adult
IgG preparations was analyzed
for concentration-dependent binding
to the immobilized GST-Du1234. In
general, a linear relationship
was observed when the amount of IgG
added varied from 0 to 2 µg
(data not shown). The difference in
reactivities among IgG preparations,
seen in Fig.
2, is therefore a
reflection of relative titers.
Adult IgG does not inhibit Fn-MSCRAMM interaction.
The ability
of the isolated adult IgG to interfere with the binding of the
125I-labeled N-terminal fragment of Fn to staphylococcal
cells or to GST-Du1234 immobilized on microtiter wells was analyzed. At 50 µg, none of the IgG preparations significantly interfered with Fn
binding to staphylococcal cells (Fig.
3A). The antibody preparations at 2 µg
did not significantly affect the binding of Fn to the immobilized
GST-Du1234 fusion protein either (Fig. 3B). Selected patient IgG
preparations were further examined for the presence of a low
concentration of antibodies capable of interfering with the
ligand-binding activity of the MSCRAMM. Thus, increasing the added IgG
from patients 1, 2, 32, and 33 up to 10 µg had no effect on Fn
binding to the immobilized GST-Du1234 (data not shown).

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 3.
Antibody preparations from patients do not inhibit Fn
binding to FnbpA. (A) Cells of S. aureus Cowan 1 (108) were incubated with 125I-labeled N29
(5 × 104) in the presence of 50 µg of each IgG
preparation, and the radioactivity bound to the cells was quantitated.
(B) GST-Du1234 was immobilized onto microtiter wells (1 µg/well) and
probed with 8 × 104 cpm of 125I-labeled
N29 in the presence of 2 µg of each IgG preparation. After being
washed extensively with PBS containing 0.1% Tween 20, the plates were
incubated with 200 µl of 2% SDS at 37°C for 30 min, and the
radioactivity released from the wells was quantitated with a gamma
counter. Controls are reported when bacteria or GST-Du1234-coated
plates were incubated without antibodies (*) or with antibodies
isolated from pooled sera from young children (**). Data are
reported as means ± standard deviations (error bars).
|
|
Patients' IgG contains anti-LIBS antibodies.
A sample of
adult IgG preparation was examined for the presence of anti-LIBS
antibodies, which recognize epitopes formed by the binding of the
ligand to the MSCRAMM (2, 3). Antibody binding to microtiter
wells coated with GST-Du1234 was enhanced by the presence of Fn for
most of the IgG preparations tested (Fig.
4). This enhanced reactivity was
specifically induced by Fn and its N-terminal fragment N29 but not
by fibrinogen and collagen, which are known to interact with
different MSCRAMM of staphylococci. When the whole panel of IgG
preparations was examined for its reactivity toward GST-Du1234 in the
presence or absence of N29, essentially all preparations showed strong
anti-LIBS activity (Fig. 5). The
extent of anti-LIBS reactivity varied from one IgG preparation to
another. For patient 23, the presence of Fn did not increase the
amount of antibody bound to the immobilized GST-Du1234 recombinant
protein. Other IgG preparations gave a signal up to fivefold
higher in the presence of the ligand. It is noteworthy that IgG from
patients 20, 22, and 28, which gave a low signal in the absence of Fn,
seemed to have a very high proportion of anti-LIBS antibodies. The
control IgG preparation contained very low anti-LIBS activity. Taken
together, these data suggest that most individuals with staphylococcal
infections develop anti-LIBS antibodies to the Fn-binding MSCRAMM. On
the other hand, fractionation of IgG from patient 23 on a
GST-Du1234-Sepharose column did not reveal any detectable anti-LIBS
antibodies (data not shown). This result is consistent with the
observation that the reactivity of this patient's IgG to GST-Du1234
was not enhanced by the presence of Fn (Fig. 5).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 4.
Specific formation of LIBS epitopes induced by Fn.
GST-Du1234 recombinant protein was immobilized onto microtiter wells (1 µg in 100 µl) and probed with each IgG preparation (2 µg in 100 µl) in the presence of Fn, the N-terminal Fn fragment (N29),
collagen, or fibrinogen. Binding of antibodies to the recombinant
protein in absence of ligand is also shown. Bound antibody was detected
as described in Materials and Methods. Bars represent means ± standard deviations with duplicate testing. Controls (*) represent
immobilized GST-Du1234 incubated with antibodies from young children.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 5.
Screening of the whole panel of IgG preparations for
anti-LIBS activity. Microtiter wells were coated with GST-Du1234 (1 µg in 100 µl) and incubated with each IgG preparation (2 µg in
100 µl) either in the absence ( ) or presence ( ) of 0.5 µg of
N29. Bound antibody was detected as described in Materials and Methods.
Data are expressed as means ± standard deviations (error bars) of
duplicate testing.
|
|
Anti-LIBS antibodies can be isolated.
To separate the
anti-LIBS antibodies from antibodies binding to the MSCRAMM in the
absence of Fn, a selected IgG preparation from patient 5 was
passed through an affinity column composed of GST-Du1234 coupled
with Sepharose. The antibodies that did not bind to the column
(flowthrough) were collected separately. The column was washed
extensively, and bound antibodies were subsequently eluted with
0.1 M glycine, pH 2.8, and neutralized. The unfractionated and
fractionated antibodies were then analyzed. By an ELISA carried out in
the presence or absence of Fn, the unfractionated antibodies gave
a stronger signal in the presence of the ligand at the different concentrations of antibody tested (Fig.
6A). Antibodies bound and eluted
from the affinity matrix gave the same response regardless of whether
Fn was present in the ELISA or not (Fig. 6C). The flowthrough IgG
preparation showed weak binding to the immobilized MSCRAMM in the
absence of Fn. When Fn was included, a markedly stronger, concentration-dependent binding of the antibody to the MSCRAMM was
noted (Fig. 6B). Fractionation of IgG from patients 15 and 26 gave
similar results. In both cases, IgG that did not bind to the
GST-Du1234-Sepharose column were highly enriched with anti-LIBS antibodies (data not shown).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 6.
ELISA of anti-LIBS antibodies isolated by affinity
chromatography on GST-Du1234. A preparation of IgG obtained from
patient 5 was fractionated onto a GST-Du1234-Sepharose column as
described in Materials and Methods. GST-Du1234 protein was immobilized
onto microtiter wells (1 µg in 100 µl) and assayed by ELISA with
increasing concentrations of IgG from the flowthrough of the column (B)
or with antibodies bound and eluted from the affinity matrix (C).
Reactivity of the unfractionated IgG preparation is shown in panel A. Assays were carried out in the absence or presence of N29. Bound
antibody was detected as described in Materials and Methods.
|
|
These results were subsequently confirmed in dot blot and Western blot
assays of IgG from patient 5 (data not shown). Unfractionated
antibody reacted with MSCRAMM in the presence and absence of
Fn,
although the presence of the ligand seemed to induce a somewhat
stronger signal. The affinity-purified antibody recognized the
MSCRAMM in the process, which was seemingly unaffected by the
presence or absence of Fn. The flowthrough IgG, on the other hand,
detected the MSCRAMM only when Fn was present in the incubation
mixture.
Localization of the LIBS epitopes.
The Fn-binding MSCRAMM
FnbpA of S. aureus contains four repeats (Du, D1, D2, and
D3) of a ligand-binding sequence and a fifth partial repeat, D4. All
these units have been shown to bind Fn (data not shown) and could
potentially form epitopes recognized by anti-LIBS antibodies. To
determine to which repeat unit(s) the LIBS antibodies were directed, we
expressed the individual units as GST fusion proteins and purified the
recombinant proteins as described previously. The whole panel of
patient IgG preparations was screened with the individual recombinant
repeat units in the presence or absence of Fn. ELISA (Fig.
7) demonstrated that the repeat units,
Du, D1, D2, and D3, as well as the incomplete repeat unit, D4, formed
epitopes in the presence of Fn which could be recognized by anti-LIBS
antibodies. These results confirm that all the individual repeat units
are capable of binding Fn and that this interaction can occur in
patients. Presumably, the binding of repeat units of the MSCRAMM to Fn
involves a conformational change in the MSCRAMM repeats which can be
manifested as an epitope recognized by an anti-LIBS antibody.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 7.
Localization of LIBS epitopes in the individual
Fn-binding motifs. The Fn-binding motifs Du, D1, D2, D3, and D4 fused
to the GST carrier were immobilized onto microtiter wells (1 µg in
100 µl) and probed with the panel of IgG preparations either in the
absence ( ) or presence ( ) of the N-terminal fragment (N29) of Fn.
Bound antibody was detected as described in Materials and Methods.
|
|
The variation in anti-LIBS antibody signals to the individual
recombinant MSCRAMM repeat units differed greatly among different
IgG
preparations. In general, most IgG preparations contained
anti-LIBS antibodies which recognized epitopes formed by the Du
and D3 repeat units, whereas only occasional IgG preparations
contained
anti-LIBS antibodies recognizing the complex formed
by the binding of
D1, D2, or D4 to Fn.
It is noteworthy that IgG from essentially all patients contained
anti-LIBS antibodies by analysis with the GST-Du1234 fragments,
whereas
IgG reactivity to individual recombinant MSCRAMM repeat
units revealed
a lower frequency of anti-LIBS antibodies. This
result is not
surprising, since anti-LIBS antibodies detected
with the GST-Du1234
fragment should include the combined reactivities
of the
anti-LIBS antibodies and those of the different individual
MSCRAMM
repeat units.
The D3 repeat unit contains a strong Fn-binding motif located in the C
terminus, corresponding to residues 15 to 36 of the
repeat, whereas
residues 1 to 21 contain one (or two) weaker Fn-binding
motifs
(data not shown). To determine if both motifs could contain
and support
the formation of epitopes recognized by anti-LIBS
antibodies, the
different D3 segments were expressed as recombinants
and targeted by
ELISA. The results of this experiment showed that
the C-terminal, but
not the N-terminal, motif could form epitopes
recognized by anti-LIBS
antibodies (Fig.
8).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 8.
Localization of LIBS epitopes in the subfragments of the
D3 motif. Microtiter wells were coated with recombinant subfragments
GST-D31-21 and GST-D315-36 (1 µg in
100 µl) and incubated with IgG preparations in either the absence
( ) or presence ( ) of N29 (see Results). Bound antibody was
detected as described in Materials and Methods.
|
|
 |
DISCUSSION |
We have analyzed the immune response to the Fn-binding
MSCRAMM in patients with S. aureus infections. The patient
population was quite varied, and in this study, we did not attempt
to correlate the immune response to onset, type of infection,
or patient group. Rather, we were interested in determining the
reactivity of antibodies produced by humans in response to
staphylococcal infection. We found that antibodies purified by affinity
chromatography on a protein A-Sepharose column bound preferentially to
the Fn-binding repeat domain of the MSCRAMM. This observation
suggests that the repeat domain is immunodominant over other MSCRAMM
domains, a conclusion which is supported by a recent study in
which ~80% of monoclonal antibodies generated from mice
immunized with the full-length MSCRAMM were found to be directed to
the repeat domain (data not shown). Alternatively, these observations
could reflect variations in serum type. Analyses of strain collections
suggest that most S. aureus strains contain the gene
encoding the Fn-binding MSCRAMM FnbpA. However, the sequence
variability of the gene in different isolates has not been determined.
The patients from whom the IgG was derived most likely were
infected by strains whose Fn-binding MSCRAMM sequences differ.
The observed low IgG binding to MSCRAMM regions outside the repeat
region may simply reflect a great sequence variability in this region
among different strains compared to a presumably conserved
ligand-binding domain.
None of the IgG preparations significantly inhibited the
binding of Fn to isolated recombinant MSCRAMM or to intact
bacteria. This surprising result does not have an obvious molecular
explanation. Is it possible that the MSCRAMM binds Fn with a much
higher affinity than a competing potentially inhibiting antibody and
that consequently inhibiting antibodies are not detected? Is the
ligand-binding surface of the MSCRAMM always occupied by Fn and
therefore never detected as foreign and a target for an immune
response? The observed conformational changes induced in the MSCRAMM on
ligand binding could help protect the binding surface of the MSCRAMM,
since it is not formed in the absence of Fn. The presence of anti-LIBS antibodies demonstrates that the Fn-MSCRAMM complex is exposed to
the immune system. Epitopes recognized by the anti-LIBS
antibodies were detected in each of the repeat units in the
ligand-binding domain when they were presented as recombinant
individual units. These observations demonstrate that each repeat unit
is capable of binding Fn and suggest that these interactions involve
conformational changes in the MSCRAMM repeat units. Furthermore, when
recombinant fragments of the D3 unit were examined, we found that the
C-terminal 20-amino-acid residues which contain a high-affinity binding
site also harbor a LIBS, suggesting that LIBS can be located close to
the ligand-binding surface. It is not clear if the LIBS is formed only
by residues in the MSCRAMM or if residues in Fn can contribute to the
epitope. So far, we have not been able to demonstrate the direct
binding of these IgG preparations to Fn by ELISA. The value of LIBS
antibodies to the patient is not known. LIBS antibodies could be
opsonic and stimulate phagocytic clearance of the bacteria. On the other hand, previous studies suggest that these antibodies may
be advantageous to bacteria by stabilizing Fn binding and thus
enhancing bacterial adherence to the host tissue (16).
Since MSCRAMM are currently being targeted in different bacterial
vaccination strategies, further studies to determine the significance
of anti-LIBS antibodies are clearly warranted.
 |
ACKNOWLEDGMENTS |
This work was supported by the Italian Ministry of
University and Scientific Research and Techology, by National
Institutes of Health grant AI20624, and by grant CRG931412 from
the North Atlantic Treaty Organization.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry, University of Pavia, Viale Taramelli 3/B, 27100 Pavia, Italy. Phone: 39 382-507 787. Fax: 39 382-423 108. E-mail:
pspeziale{at}ipv36.unipv.it.
Editor:
V. A. Fischetti
 |
REFERENCES |
| 1.
|
Courtney, H. S.,
Y. Li,
J. B. Dale, and D. L. Hasty.
1994.
Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci.
Infect. Immun.
62:3937-3946[Abstract/Free Full Text].
|
| 2.
|
Frelinger, A. L.,
I. Cohen,
E. F. Plow,
M. A. Smith,
J. Roberts,
S. C. Lam, and M. H. Ginsberg.
1990.
Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers.
J. Biol. Chem.
265:6346-6352[Abstract/Free Full Text].
|
| 3.
|
Frelinger, A. L.,
X. Du,
E. F. Plow, and M. H. Ginsberg.
1991.
Monoclonal antibodies to ligand-occupied conformers of integrin IIb 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function.
J. Biol. Chem.
266:17105-17111.
|
| 4.
|
Frick, I.-M.,
K. L. Crossin,
G. M. Edelman, and L. Biörck.
1995.
Protein H a bacterial surface protein with affinity for both immunoglobulin and fibronectin type III domains.
EMBO J.
14:1674-1679[Medline].
|
| 5.
|
Hanski, E., and M. Caparon.
1992.
Protein F, a fibronectin-binding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes.
Proc. Natl. Acad. Sci. USA
89:6172-6176[Abstract/Free Full Text].
|
| 6.
|
House-Pompeo, K.,
Y. Xu,
D. Joh,
P. Speziale, and M. Höök.
1996.
Conformational changes in the fibronectin binding MSCRAMM are induced by ligand binding.
J. Biol. Chem.
271:1379-1384[Abstract/Free Full Text].
|
| 7.
|
Joh, H. J.,
K. House-Pompeo,
J. M. Patti,
S. Gurusiddappa, and M. Höök.
1994.
Fibronectin receptors from Gram-positive bacteria: comparison of active sites.
Biochemistry
33:6086-6092[Medline].
|
| 8.
|
Jönsson, C.,
C. Signäs,
H. P. Müller, and M. Lindberg.
1991.
Two different genes encode fibronectin-binding proteins in Staphylococcus aureus. The complete nucleotide sequence and characterization of the second gene.
Eur. J. Biochem.
202:1041-1048[Medline].
|
| 9.
|
Lindgren, P.-E.,
M. J. McGavin,
C. Signäs,
B. Guss,
S. Gurusidappa,
M. Höök, and M. Lindberg.
1993.
Two different genes coding for fibronectin-binding proteins from Streptococcus dysgalactiae.
Eur. J. Biochem.
214:819-827[Medline].
|
| 10.
|
Panchioli, V., and V. A. Fischetti.
1992.
A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate dehydrogenase with multiple binding activity.
J. Exp. Med.
176:415-426[Abstract/Free Full Text].
|
| 11.
|
Patti, J. M.,
B. L. Allen,
M. J. McGavin, and M. Höök.
1994.
MSCRAMM-mediated adherence of microorganisms to host tissues.
Annu. Rev. Microbiol.
48:585-617[Medline].
|
| 12.
|
Patti, J. M., and M. Höök.
1994.
Microbial adhesins recognizing extracellular matrix macromolecules.
Curr. Opin. Cell Biol.
6:752-758[Medline].
|
| 13.
|
Rakonjac, J. V.,
J. C. Robbins, and V. A. Fischetti.
1995.
DNA sequence of the serum opacity factor of group A streptococci: identification of a fibronectin binding repeat domain.
Infect. Immun.
63:622-631[Abstract].
|
| 14.
|
Schmidt, K. H.,
K. Mann,
J. Cooney, and W. Köhler.
1993.
Multiple binding of type 3 streptococcal M protein to human fibrinogen, albumin and fibronectin.
FEMS Immun. Med. Microbiol.
7:135-144[Medline].
|
| 15.
|
Signäs, C.,
G. Raucci,
K. Jönsson,
P.-E. Lindgren,
G. M. Anantharamaiah,
M. Höök, and M. Lindberg.
1989.
Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus and its use in the synthesis of biologically active peptides.
Proc. Natl. Acad. Sci. USA
86:699-703[Abstract/Free Full Text].
|
| 16.
|
Speziale, P.,
D. Joh,
L. Visai,
S. Bozzini,
K. House-Pompeo,
M. Lindberg, and M. Höök.
1996.
A monoclonal antibody enhances ligand binding of fibronectin MSCRAMM adhesin from Streptococcus dysgalactiae.
J. Biol. Chem.
271:1371-1378[Abstract/Free Full Text].
|
| 17.
|
Talay, S. R.,
P. Valentin-Weigand,
K. N. Timmis, and G. S. Chhatwal.
1994.
Domain structure and conserved epitopes of the Sfb protein, the fibronectin-binding adhesin of Streptococcus pyogenes.
Mol. Microbiol.
13:531-539[Medline].
|
| 18.
|
Vuento, M., and A. Vaheri.
1979.
Purification of fibronectin from human plasma by affinity chromatography under non-denaturing conditions.
Biochem. J.
183:331-337[Medline].
|
Infection and Immunity, November 1998, p. 5433-5442, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Meenan, N. A. G., Visai, L., Valtulina, V., Schwarz-Linek, U., Norris, N. C., Gurusiddappa, S., Hook, M., Speziale, P., Potts, J. R.
(2007). The Tandem beta-Zipper Model Defines High Affinity Fibronectin-binding Repeats within Staphylococcus aureus FnBPA. J. Biol. Chem.
282: 25893-25902
[Abstract]
[Full Text]
-
Dryla, A., Prustomersky, S., Gelbmann, D., Hanner, M., Bettinger, E., Kocsis, B., Kustos, T., Henics, T., Meinke, A., Nagy, E.
(2005). Comparison of Antibody Repertoires against Staphylococcus aureus in Healthy Individuals and in Acutely Infected Patients. CVI
12: 387-398
[Abstract]
[Full Text]
-
Kim, J. H., Singvall, J., Schwarz-Linek, U., Johnson, B. J. B., Potts, J. R., Hook, M.
(2004). BBK32, a Fibronectin Binding MSCRAMM from Borrelia burgdorferi, Contains a Disordered Region That Undergoes a Conformational Change on Ligand Binding. J. Biol. Chem.
279: 41706-41714
[Abstract]
[Full Text]
-
Haggar, A., Hussain, M., Lonnies, H., Herrmann, M., Norrby-Teglund, A., Flock, J.-I.
(2003). Extracellular Adherence Protein from Staphylococcus aureus Enhances Internalization into Eukaryotic Cells. Infect. Immun.
71: 2310-2317
[Abstract]
[Full Text]
-
Roche, F. M., Massey, R., Peacock, S. J., Day, N. P. J., Visai, L., Speziale, P., Lam, A., Pallen, M., Foster, T. J.
(2003). Characterization of novel LPXTG-containing proteins of Staphylococcus aureus identified from genome sequences. Microbiology
149: 643-654
[Abstract]
[Full Text]
-
Etz, H., Minh, D. B., Henics, T., Dryla, A., Winkler, B., Triska, C., Boyd, A. P., Sollner, J., Schmidt, W., von Ahsen, U., Buschle, M., Gill, S. R., Kolonay, J., Khalak, H., Fraser, C. M., von Gabain, A., Nagy, E., Meinke, A.
(2002). Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. USA
99: 6573-6578
[Abstract]
[Full Text]
-
Rice, K., Huesca, M., Vaz, D., McGavin, M. J.
(2001). Variance in Fibronectin Binding and fnb Locus Polymorphisms in Staphylococcus aureus: Identification of Antigenic Variation in a Fibronectin Binding Protein Adhesin of the Epidemic CMRSA-1 Strain of Methicillin-Resistant S. aureus. Infect. Immun.
69: 3791-3799
[Abstract]
[Full Text]
-
Nallapareddy, S. R., Singh, K. V., Duh, R.-W., Weinstock, G. M., Murray, B. E.
(2000). Diversity of ace, a Gene Encoding a Microbial Surface Component Recognizing Adhesive Matrix Molecules, from Different Strains of Enterococcus faecalis and Evidence for Production of Ace during Human Infections. Infect. Immun.
68: 5210-5217
[Abstract]
[Full Text]
-
McCrea, K. W., Hartford, O., Davis, S., Eidhin, D. N., Lina, G., Speziale, P., Foster, T. J., Höök, M.
(2000). The serine-aspartate repeat (Sdr) protein family in Staphylococcus epidermidis. Microbiology
146: 1535-1546
[Abstract]
[Full Text]
-
Huesca, M., Sun, Q., Peralta, R., Shivji, G. M., Sauder, D. N., McGavin, M. J.
(2000). Synthetic Peptide Immunogens Elicit Polyclonal and Monoclonal Antibodies Specific for Linear Epitopes in the D Motifs of Staphylococcus aureus Fibronectin-Binding Protein, Which Are Composed of Amino Acids That Are Essential for Fibronectin Binding. Infect. Immun.
68: 1156-1163
[Abstract]
[Full Text]
-
Colque-Navarro, P., Palma, M., Soderquist, B., Flock, J.-I., Mollby, R.
(2000). Antibody Responses in Patients with Staphylococcal Septicemia against Two Staphylococcus aureus Fibrinogen Binding Proteins: Clumping Factor and an Extracellular Fibrinogen Binding Protein. CVI
7: 14-20
[Abstract]
[Full Text]